Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong
March 3, 2021
- MSD Files Refractory Cough Medicine in Japan
March 3, 2021
- Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
- Mitsubishi Tanabe Licenses Therapeutic App for Depression to DT Axis
March 3, 2021
- Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
- Comirnaty Label Updated in Japan to Ease Storage Temperature: Pfizer/BioNTech
March 2, 2021
- Ono, PeptiDream Ink License Pact for Peptide Drug Discovery
March 2, 2021
- Kissei Seeks Approval for C5aR Inhibitor Avacopan in Japan
March 2, 2021
- Idorsia Files Japan NDA for Clazosentan
March 2, 2021
- Online Meeting Promotions Rise on Decrease in Face-to-Face Visits, In-Hospital Seminars in December: Intage
March 2, 2021
- Kyowa Kirin, Harvard Form Strategic Research Alliance
March 1, 2021
- Daiichi Sankyo to Divest 11 Off-Patent Brands to Alfresa
March 1, 2021
- Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
- UCB Files Psoriasis Med Bimekizumab for Japan Approval
March 1, 2021
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…